Nehal J. Lakhani, MD, PhD
In The Press Publications News & Blog
Nehal J. Lakhani, MD, PhD Read More »
Why Adaptive Clinical Trials in Community Settings are the Future of Cancer Research
Randomized clinical trials (RCTs) began in the 1940s with streptomycin’s evaluation against tuberculosis. Since then, RCTs have been the foundation of clinical trial design, ensuring therapies reach patients safely. For decades, oncology trials followed a set pattern: drugs were tested in preclinical models, followed by dose escalation to assess safety, toxicity, and efficacy compared to
Why Adaptive Clinical Trials in Community Settings are the Future of Cancer Research Read More »
Capturing the Complexity of Real Cancer Cases with Patient-Derived Xenograft Models
Capturing the Complexity of Real Cancer Cases with Patient-Derived Xenograft Models One of the most significant areas of advancement in oncology is the growing capacity to match patients with therapies tailored to their unique cancer. As more relevant biomarkers and druggable targets are identified, drug developers still face an evergreen challenge: narrowing down the most
Capturing the Complexity of Real Cancer Cases with Patient-Derived Xenograft Models Read More »
Community-Based Clinical Trials: A Catalyst for Advancing Targeted Therapies
Accelerating Targeted Cancer Therapy Trials: Perspectives from START Key Highlights Significant increase in FDA-approved targeted cancer therapies over the past decade. Low prevalence of specific mutations and variable toxicities of targeted therapies are important challenges to consider when starting a trial. Selecting sites with expertise is crucial to timely completion of trials with accurate reporting.
Community-Based Clinical Trials: A Catalyst for Advancing Targeted Therapies Read More »
